Global Non Alcoholic Steatohepatitis NASH Market Report 2024

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2023 – By Type (Solid, Liquid), By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products), By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By Sales Channel (Hospital Pharmacy, Retail Pharmacy, Online Provider), By Application (Oral, Parenteral) – Market Size, Trends, And Market Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : July 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Non-Alcoholic Steatohepatitis (NASH) Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.

The main types of non-alcoholic steatohepatitis (NASH) are solid and liquid. Solid is primarily created as crystalline solid forms that are sold as tablets for oral consumption, due to its excellent purity and durability. The products involved are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, and cenicriviroc, and others that are used for different disease causes such as hypertension, heart disease, high blood lipid, type 2 diabetes, obesity, and sold by the hospital pharmacy, retail pharmacy, online providers. It includes oral and parenteral applications.

The global non-alcoholic steatohepatitis (NASH) market is segmented -

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

The global non alcoholic steatohepatitis (NASH) market is expected to grow from $2.42 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 34.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global non alcoholic steatohepatitis (NASH) market is expected to grow to $10.73 billion in 2027 at a CAGR of 34.7%.

The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As nonalcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in April 2021, according to the COVID-19 and Obesity: The 2021 Atlas, a report published by the World Obesity Federation, a UK-based federation that represents professional members of the scientific 2021, percentage of overweight adults recorded more than 60% of the US population, however, the obesity percentage of male expected to reach 44.2% and female 44.4% by 2025 in the US population. Therefore, the rise in the cases of obesity will drive the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Major players in the non alcoholic steatohepatitis (nash) market are AstraZeneca plc., Arena Pharmaceuticals Inc., GSK plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Vivus LLC, Arisaph Pharmaceuticals Inc., Cempra Pharmaceuticals Inc., Galectin Therapeutics Inc., Galmed Pharmaceuticals Inc., Genfit SA, Gilead Sciences Inc., Immuron Limited, Raptor Pharmaceutical Inc., The Takeda Pharmaceutical Company Limited, Tobira Therapeutics Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Cadila Pharmaceuticals Ltd., Novartis AG, Conatus Pharmaceuticals Inc., One Way Liver S.L., and BioPredictive S.A.S.

Technological advancement is a key trend gaining popularity in the non-alcoholic steatohepatitis (NASH) market. Major players in the non-alcoholic steatohepatitis (NASH) market are focused on technological advancement to sustain their marketplace. For instance, in May 2021, GENFIT Inc., a France-based biotechnology company launched NASHnext, a brand-new non-invasive test for diagnosing non-alcoholic steatohepatitis (NASH). NIS4TM, a GENFIT-exclusive screening technology that uses a revolutionary blood-based molecular biomarker test to detect NASH and severe fibrosis, powers NASHnext. The test is only made available in the United States and Canada by Labcorp, one of the top worldwide life sciences businesses.

In July 2022, Advanz Pharma Corp. Limited, a UK-based pharmaceutical company acquired Intercept Pharmaceuticals Inc for an undisclosed amount. With this deal, Advanz Pharma aims to have a significant presence in the treatment of rare diseases by including the ex-U.S. rights to the orphan medicine Ocaliva (obeticholic acid), which is used to treat primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc is a US-based biopharmaceutical company focused on creating and marketing cutting-edge therapies for the treatment of progressive non-viral liver disorders.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2022. The regions covered in the global non alcoholic steatohepatitis (NASH) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non alcoholic steatohepatitis (NASH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of nonalcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Non Alcoholic Steatohepatitis (NASH) Market Characteristics

    3. Non Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

    4. Non Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario

    4.1. COVID-19 Impact On Non Alcoholic Steatohepatitis (NASH) Market

    4.2. Ukraine-Russia War Impact On Non Alcoholic Steatohepatitis (NASH) Market

    4.3. Impact Of High Inflation On Non Alcoholic Steatohepatitis (NASH) Market

    5. Non Alcoholic Steatohepatitis (NASH) Market Size And Growth

    5.1. Global Non Alcoholic Steatohepatitis (NASH) Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Non Alcoholic Steatohepatitis (NASH) Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Non Alcoholic Steatohepatitis (NASH) Market Segmentation

    6.1. Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Solid

    Liquid

    6.2. Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Vitamin E And Pioglitazone

    Ocaliva

    Elafibranor

    Selonsertib And Cenicriviroc

    Other Products

    6.3. Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hypertension

    Heart Disease

    High Blood Lipid

    Type 2 Diabetes

    Obesity

    6.4. Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Provider

    6.5. Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oral

    Parenteral

    7. Non Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

    7.1. Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Non Alcoholic Steatohepatitis (NASH) Market  

    8.1. Asia-Pacific Non Alcoholic Steatohepatitis (NASH) Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Non Alcoholic Steatohepatitis (NASH) Market  

    9.1. China Non Alcoholic Steatohepatitis (NASH) Market Overview  

    9.2. China Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Non Alcoholic Steatohepatitis (NASH) Market  

    10.1. India Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Non Alcoholic Steatohepatitis (NASH) Market  

    11.1. Japan Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Non Alcoholic Steatohepatitis (NASH) Market  

    12.1. Australia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Non Alcoholic Steatohepatitis (NASH) Market  

    13.1. Indonesia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Non Alcoholic Steatohepatitis (NASH) Market  

    14.1. South Korea Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Non Alcoholic Steatohepatitis (NASH) Market  

    15.1. Western Europe Non Alcoholic Steatohepatitis (NASH) Market Overview

    15.2. Western Europe Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Non Alcoholic Steatohepatitis (NASH) Market  

    16.1. UK Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Non Alcoholic Steatohepatitis (NASH) Market  

    17.1. Germany Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Non Alcoholic Steatohepatitis (NASH) Market  

    18.4. France Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Non Alcoholic Steatohepatitis (NASH) Market  

    19.1. Eastern Europe Non Alcoholic Steatohepatitis (NASH) Market Overview

    19.2. Eastern Europe Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Non Alcoholic Steatohepatitis (NASH) Market  

    20.1. Russia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Non Alcoholic Steatohepatitis (NASH) Market  

    21.1. North America Non Alcoholic Steatohepatitis (NASH) Market Overview

    21.2. North America Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Non Alcoholic Steatohepatitis (NASH) Market  

    22.1. USA Non Alcoholic Steatohepatitis (NASH) Market Overview

    22.2. USA Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Non Alcoholic Steatohepatitis (NASH) Market  

    23.1. South America Non Alcoholic Steatohepatitis (NASH) Market Overview

    23.2. South America Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Non Alcoholic Steatohepatitis (NASH) Market  

    24.1. Brazil Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Non Alcoholic Steatohepatitis (NASH) Market  

    25.1. Middle East Non Alcoholic Steatohepatitis (NASH) Market Overview

    25.2. Middle East Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Non Alcoholic Steatohepatitis (NASH) Market  

    26.1. Africa Non Alcoholic Steatohepatitis (NASH) Market Overview

    26.2. Africa Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Non Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

    27.1. Non Alcoholic Steatohepatitis (NASH) Market Competitive Landscape

    27.2. Non Alcoholic Steatohepatitis (NASH) Market Company Profiles

    27.2.1. AstraZeneca plc.

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Arena Pharmaceuticals Inc.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. GSK plc.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novo Nordisk A/S

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. F. Hoffmann-La Roche AG

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Non Alcoholic Steatohepatitis (NASH) Market

    29. Non Alcoholic Steatohepatitis (NASH) Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Historic And Forecast Inflation Rates

    30.4. Research Inquiries

    30.5. The Business Research Company

    30.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: Asia-Pacific, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: China, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: China, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: India, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: India, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Japan, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Japan, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Australia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Australia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Indonesia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: Indonesia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: South Korea, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: South Korea, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Western Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Western Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: UK, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: UK, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: Germany, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: Germany, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: France, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: France, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Eastern Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Eastern Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: Russia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: Russia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: North America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: North America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: USA, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: USA, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: South America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: South America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Brazil, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Brazil, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Middle East, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Middle East, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Africa, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: Africa, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 48: AstraZeneca plc. Financial Performance
  • Table 49: Arena Pharmaceuticals Inc. Financial Performance
  • Table 50: GSK plc. Financial Performance
  • Table 51: Novo Nordisk A/S Financial Performance
  • Table 52: F. Hoffmann-La Roche AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Global Non Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: Asia-Pacific, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: China, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: China, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: India, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: India, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Japan, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Japan, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Australia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Australia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Indonesia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: Indonesia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: South Korea, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: South Korea, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Western Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Western Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: UK, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: UK, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: Germany, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: Germany, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: France, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: France, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Eastern Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Eastern Europe, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: Russia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: Russia, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: North America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: North America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: USA, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: USA, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: South America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: South America, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Brazil, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Brazil, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Middle East, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Middle East, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Africa, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: Africa, Non Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 48: AstraZeneca plc. Financial Performance
  • Figure 49: Arena Pharmaceuticals Inc. Financial Performance
  • Figure 50: GSK plc. Financial Performance
  • Figure 51: Novo Nordisk A/S Financial Performance
  • Figure 52: F. Hoffmann-La Roche AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report